Cas:1116-45-6 (2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate manufacturer & supplier

Chemical Name:(2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate

CAS.NO:1116-45-6

Synonyms:Glycerin-1,2-dipalmitat-3-hexadecylether;1-O-hexyadecyl-2,3-dipalmitoyl-rac-glycerol;CHIMYL DIPALMITATE;1-O-hexadecyl-2,3-dihexadecanoylglycerol;1,2-Dipalmitoyl-3-O-palmityl-rac-glycerol;1-O-hexadecyl-2,3-O-dihexadecanoyl glycerol;1-O-Hexadecyl-2,3-dihexadecanoyl-rac-glycerol

Molecular Formula:C₅₁H₁₀₀O₅

Molecular Weight:793.33700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:769.1ºC at 760mmHg

Density:0.897g/cm3

Index of Refraction:1.463

PSA:61.83000

Exact Mass:792.75700

LogP:16.90190

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Glycerin-1,2-dipalmitat-3-hexadecylether chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-O-Hexadecyl-2,3-dihexadecanoyl-rac-glycerol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-O-Hexadecyl-2,3-dihexadecanoyl-rac-glycerol Use and application,CHIMYL DIPALMITATE technical grade,usp/ep/jp grade.

Related News: Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. (2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate manufacturer ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. (2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate supplier We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. (2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate vendor We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. (2-hexadecanoyloxy-3-hexadecoxypropyl) hexadecanoate factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.